• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Pivotal study to evaluate AuroLase therapy for prostate tissue ablation

Article

Nanospectra Biosciences, Inc. recently announced the start of a pivotal study to determine the efficacy of using magnetic resonance imaging/ultrasound fusion imaging technology to direct focal ablation of prostate tissue using nanoparticle-directed laser ablation.

Nanospectra Biosciences, Inc. recently announced the start of a pivotal study to determine the efficacy of using magnetic resonance imaging/ultrasound fusion imaging technology to direct focal ablation of prostate tissue using nanoparticle-directed laser ablation.

The initial two patient procedures in the pivotal trial have been completed at the University of Michigan, Ann Arbor, which also participated in the pilot study. The AuroLase pivotal study follows the successful first-in-human pilot study that enrolled 46 subjects at three U.S. sites.

Clinical and functional outcomes of a subset of subjects at the lead site in the feasibility study were published in Proceedings of the National Academy of Sciences (2019; 116:18590-6). Thirteen of the first 15 prostate cancer patients treated in the clinical trial of the nanoparticle-based focal therapy showed no detectable signs of cancer upon biopsy in the target ablation zone a year after treatment. The final results of the feasibility study are expected later this year.

The pivotal study is an open-label, multicenter, single-treatment study of AuroLase Therapy for the focal ablation of prostate tissue via nanoparticle-directed near infrared irradiation and approved by the FDA under the original Investigational Device Exemption. Up to 60 patients will be enrolled at up to eight clinical trial sites throughout the U.S.

Efficacy of focal ablation of prostate tissue will be assessed by MRI/ultrasound-guided target biopsy 6 months after laser treatment and at 1 year via targeted biopsy and standard systematic biopsy.

Ardeshir Rastinehad, DO, of Lenox Hill Urology and Northwell Health System, New York and the initial study’s lead principal investigator, presented preliminary feasibility study data at the International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer in Washington.

Related Videos
Samuel L. Washington III, MD, MAS, answers a question during a Zoom video interview
Conceptual image for prostate cancer treatment | © Dr_Microbe - stock.adobe.com
Female doctor talking with male patient | Image Credit: © Prostock-studio - stock.adobe.com
Daniel A. Triner, MD, PhD, answers a question during a Zoom video interview
Video 2 - "Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer"
Video 1 - "Metastatic Prostate Cancer: Background and Patient Prognosis"
Prostate cancer, 3D illustration showing presence of tumor inside prostate gland which compresses urethra | Image Credit: © Dr_Microbe - stock.adobe.com
Doctor consulting with patient | Image Credit: © Khunatorn - stock.adobe.com
Scott Morgan, MD, MSc, FRCPC, answers a question during a Zoom video interview
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.